Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819990 | 0.86 | CHRNB2 (0.41) | DPP4CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL2739927 | 0.82 | DPP4 (0.54) | DPP4CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25447885 | 0.82 | CHRNB2 (0.38) | DPP4CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL18016219 | 0.82 | CHRNB2 (0.45) | DPP4CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL26775895 | 0.81 | DPP4 (0.55) | DPP4DPP7 | |
| SCHEMBL14737113 | 0.81 | DPP4 (0.55) | DPP4DPP7 | |
| SCHEMBL14737115 | 0.81 | DPP4 (0.55) | DPP4DPP7 | |
| SCHEMBL13819919 | 0.80 | CHRNB2 (0.43) | DPP4CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL2739928 | 0.79 | DPP4 (0.47) | DPP4CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL25447005 | 0.79 | CHRNB2 (0.36) | DPP4CHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-05-18 | — | — | US | disclosed |
| WO-2023027948-A1 | JAK2 INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-11034660-B2 | Hydrazide containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200339521-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2020-10-29 | — | — | US | disclosed |
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2007047496-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | DPP4 463/4885CHRNB2 1900/4885CHRNA3 1762/4885 |
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | DPP4 3765/4885CHRNB2 3189/4885CHRNA3 3424/4885 |
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | DPP4 1318/4885CHRNB2 4483/4885CHRNA3 4269/4885 |
| US-20200339521-A1 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, KPNA1, ABCB11 | DPP4 2337/4885CHRNB2 3401/4885CHRNA3 2610/4885 |
| US-20090012080-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1525/4885CHRNB2 3635/4885CHRNA3 3432/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | DPP4 1992/4885CHRNB2 2017/4885CHRNA3 3116/4885 |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | MCL1, BCL2A1, BCL2L1 | DPP4 4838/4885CHRNB2 4868/4885CHRNA3 4866/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | DPP4 603/4885CHRNB2 3277/4885CHRNA3 2981/4885 |
| US-20230151027-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, SLC10A1, NR1H4 | DPP4 1086/4885CHRNB2 4863/4885CHRNA3 4755/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | DPP4 1889/4885CHRNB2 2021/4885CHRNA3 3069/4885 |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | DPP4 1230/4885CHRNB2 3689/4885CHRNA3 3873/4885 |
| US-11034660-B2 | Hydrazide containing nuclear transport modulators and uses thereof | XPO1, KPNA1, ABCB11 | DPP4 2337/4885CHRNB2 3401/4885CHRNA3 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.